46 completed, 9 terminated, 7 unknown, 5 recruiting. 77 Phase 2, 8 Phase 1, 4 Phase 3.
Follow Denosumab: new trials by email Literature Review of Denosumab trials Research Report on Denosumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 110 | 2026-10-31 | 2026-09-11 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Denosumab Strategy for Liver Cancer With Bone Metastases Denosumab, Sintilimab, Delayed/Rescue Bone-Modifying Strategy - Hepatocellular Carcinoma (HCC), Bone Metastases | Phase 2 | Not yet recruiting | Tongji Hospital | 50 | 2026-05-01 | 2026-04-17 |
| Denosumab for Type 1 Diabetes Denosumab, Placebo - Type 1 Diabetes | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 45 | 2025-05-05 | 2026-10-20 |
| NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia Denosumab (Prolia), Letrozole (Aromatase Inhibitors) - Infertility, Male | Phase 1 / Phase 2 | Completed | Martin Blomberg Jensen | 16 | 2025-03-01 | 2026-10-21 |
| Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis Zumsemetinib, Capecitabine, Zoledronic acid - Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 152 | 2025-01-30 | 2026-10-13 |
| An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting Denosumab, tislelizumab, Docetaxel - Lung Cancer | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 22 | 2024-11-19 | 2024-12-27 |
| NAPO - Novel Approach for Oligospermia Denosumab, sodium chloride - Infertility, Male | Phase 1 / Phase 2 | Completed | Martin Blomberg Jensen | 42 | 2024-03-01 | 2025-12-19 |
| Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia denosumab - Fibrous Dysplasia | Phase 2 | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 15 | 2022-10-12 | 2026-01-20 |
| Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis JMT103, Denosumab, Placebo - Postmenopausal Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 200 | 2022-04-21 | 2022-07-18 |
| FITMI - First In Treating Male Infertility Denosumab, Sodium chloride - Infertility, Male | Phase 2 | Active not recruiting | Martin Blomberg Jensen | 180 | 2022-01-01 | 2024-11-15 |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) RXC004, Denosumab, pembrolizumab - Advanced Solid Tumours | Phase 2 | Completed | Redx Pharma Ltd | 45 | 2021-12-10 | 2025-03-17 |
| A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) RXC004, Nivolumab, Denosumab - Colorectal Cancer | Phase 2 | Completed | Redx Pharma Ltd | 25 | 2021-11-08 | 2025-04-16 |
| Denosumab and Screw Fixation for Osteoporotic Compression Fracture Denosumab Only Product - Denosumab Allergy | Phase 2 / Phase 3 | Withdrawn | Shenzhen People's Hospital | 2021-09-14 | 2023-03-14 | |
| Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture Denosumab, Zoledronic acid - Denosumab vs Zoledronate | Phase 2 / Phase 3 | Unknown | Shenzhen People's Hospital | 122 | 2021-09-08 | 2023-02-21 |
| Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9% or 5% Dextrose Intravenous - Critical Illness, Osteoporosis | Phase 2 | Recruiting | Australian and New Zealand Intensive Care Research Centre | 450 | 2021-07-15 | 2026-03-04 |
| Romosozumab/Denosumab Study for Premenopausal IOP Romosozumab Prefilled Syringe [Evenity], Denosumab 60 MG/ML Prefilled Syringe [Prolia] - Premenopausal Idiopathic Osteoporosis | Phase 2 | Active not recruiting | Columbia University | 30 | 2021-03-12 | 2026-02-27 |
| Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI Romosozumab, Denosumab, Placebo - Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI | Phase 2 | Completed | VA Office of Research and Development | 36 | 2021-03-01 | 2026-09-21 |
| A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients. Denosumab Injection, Placebos - Osteoporosis | Phase 2 | Withdrawn | Albert Einstein Healthcare Network | 2020-07-01 | 2020-06-26 | |
| The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients Denosumab Inj 60 mg/ml, Placebo - Osteoporosis, Renal Osteodystrophy | Phase 2 | Terminated | Thomas Nickolas, MD MS | 8 | 2020-01-16 | 2024-07-25 |
Showing 20 of 77. Sign in to see all of them.
Osteoporosis (15) · Breast Neoplasms (10) · Multiple Myeloma (5) · Neoplasms (5) · Bone Diseases, Metabolic (4) · Infertility, Male (4) · Neoplasm Metastasis (4) · Osteoporosis, Postmenopausal (4) · Giant Cell Tumor of Bone (3) · Kidney Neoplasms (3) · Arthritis (2) · Arthritis, Rheumatoid (2) · Bone Cysts, Aneurysmal (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2)
Amgen (12) · Martin Blomberg Jensen (5) · Shenzhen People's Hospital (3) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · National Institute of Dental and Craniofacial Research (NIDCR) (2) · Redx Pharma Ltd (2) · Washington University School of Medicine (2) · Ain Shams University (1) · Albert Einstein Healthcare Network (1) · Alison Stopeck (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Australian and New Zealand Intensive Care Research Centre (1) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Borstkanker Onderzoek Groep (1)
United States (29) · Australia (7) · Canada (7) · China (7) · United Kingdom (7) · Denmark (5) · France (5) · Germany (5) · Italy (5) · Netherlands (5) · Greece (3) · Spain (3) · Sweden (3) · Austria (2) · Belgium (2)
Adi Cohen, MD (2) · Alison M Boyce, M.D. (2) · Elizabeth Shane, MD (2) · Naoto Ueno, MD, PHD (2) · Sam Kafai Yahyavi, MD (2) · AJ Gelderblom, Prof (1) · Adetunji T Toriola, M.D., Ph.D. (1) · Alison Stopeck, MD (1) · August Verbruggen, Prof Dr. Em. (1) · Benjamin Z Leder, MD (1) · Brea Lipe (1) · Catherine Anastasopoulou, MD, PhD (1) · Charles N Bernstein, MD (1)
PMID 38979716, PMID 16495394, PMID 17708711, PMID 18495508, PMID 18539106, PMID 19237632, PMID 19524963, PMID 19732857, PMID 21927920, PMID 23234632, PMID 23683600, PMID 23990665, PMID 24382002, PMID 24420643, PMID 25684041, PMID 25882205, PMID 26070551, PMID 26144908, PMID 26227196, PMID 26467455, PMID 26687949, PMID 26964731, PMID 27108405, PMID 27733431, PMID 29211870, PMID 29555836, PMID 30231890, PMID 30381400, PMID 31589776, PMID 31849202, PMID 33270906, PMID 33303745, PMID 33305593, PMID 33482769, PMID 33811034, PMID 33913339, PMID 34252375, PMID 34530172, PMID 34849989, PMID 35588050, PMID 35733213, PMID 36812441, PMID 37323099, PMID 37449658, PMID 38378678, PMID 38522503, PMID 39248270, PMID 39280787, PMID 40050004, PMID 40055742
2016 (2), 2008 (1), 2014 (1), 2015 (1), 2018 (1), 2023 (1), I01RX003415 (1), P30CA060553 (1), R37CA235602 (1), U10CA180886 (1)